May 11, 2011 by Brian Orelli, PhDBoston Scientific Investors' Parting GiftLess than two years in, Elliot is out.
May 10, 2011 by Brian Orelli, PhDPfizer's Multibillion-Dollar Blockbuster Set to GrowPfizer will make money off old people, too.
May 10, 2011 by Brian Orelli, PhDUncontrolled Crying Over AVANIR's Prescription Data?A slow start, but don't write off the company yet.
May 9, 2011 by Brian Orelli, PhDIn Biotech, Two Platforms Are Better Than OneAlkermes buys Elan Drug Technology.
May 4, 2011 by Brian Orelli, PhDVIVUS Unveils Its Obesity Plans But Qnexa's pathway to approval is still cloudy.
May 4, 2011 by Brian Orelli, PhDCell Therapeutics: Denied but Not RejectedThis Hail Mary pass hasn't hit the ground yet.
May 4, 2011 by Brian Orelli, PhDFor Pfizer, Breaking Up Is Hard to DoThis split won't happen too quickly.
May 2, 2011 by Brian Orelli, PhDProstate Cancer Drug Roars AheadJohnson & Johnson's buy of Cougar paid off, but look in the rearview mirror.
May 2, 2011 by Brian Orelli, PhDThe Spectrum of Biotech ValuationsSpectrum Pharma isn't on the winning end.
May 2, 2011 by Brian Orelli, PhDStemCells Up for All the Right ReasonsFederal funding doesn't matter for most stem cell companies.
Apr 29, 2011 by Brian Orelli, PhDOral Multiple Sclerosis Drugs Heat UpWatch out Novartis and Gilenya.
